Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 23, 1993 - Issue 7
11
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Metabolic fate of a new dihydropyridine calcium antagonist, CD-349, in rat and dog

, , , &
Pages 747-759 | Received 21 Dec 1992, Accepted 06 May 1993, Published online: 23 Apr 2010

References

  • Higuchi S., Sasaki H., Shiobara Y., Sado T. Absorption, excretion and metabolism of a new dihydropyridine diester cerebral vasodilator in rats and dogs. Xenobiotica 1977; 7: 469–479
  • Higuchi S., Shiobara Y. Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. Xenobiotica 1980; 10: 889–896
  • Ignarro L. J., Lipton H., Edwords J. C., Baricos W. H., Hymann A. L., Kadwitz P. Z., Gruetter C. A. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide. Journal of Pharmacology and Experimental Therapeutics 1981; 218: 739–749
  • Kobayashi Y., Okumura S., Kosaka Y., Kobayashi S., Inoue A., Oka T., Nakamizo N. Identification of benidipine hydrochloride metabolites in rats and dogs. Arzneimittel-Forschung 1988; 38: 1753–1756
  • Medenwald H., Schlossman K., Wunsche C. Structuraufklarung der renalen ausscheidungsprodukte von 4-(2-nitrophenyl)-2, 6-dimethyl-1, 4-dihydropyridin-3, 5-di-carbonsaure-dimethylester. Arzneimittel-Forschung 1972; 22: 53–56
  • Miyata N., Tsuchida K., Otomo S. Protein kinase C-mediated contraction in rabbit aorta is inhibited by CD-349, a dihydropyridine derivative. Journal of Cardiovascular Pharmacology 1991; 17: 786–791
  • Ogawa T., Nakashima Y., Nakasato A., Kumazawa Y., Kawase M., Tsuchida K., Sota K. Synthesis and antihypertensive effect of the metabolites of 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-(2-nitroxypropyl) ester 5-(3-nitroxypropyl) ester (CD-349)Presented at the Japanese-United States Congress of Pharmaceutical Sciences, Honolulu, Hawaii, December2–7, 1987
  • Parinov V. J., Odinec A. G., Gilev A. P., Dubur G. J., Muceniece D. H., Ozol J. J., Shatz V. D., Gavars M. P., Vigante B. A. Pharmacokinetics and metabolism of ryodipine in rats. Arzneimittel- Forschung 1985; 35: 808–813
  • Regardh C. G., Baarnhielm C., Edgar B., Hoffmann K.-J. Pharmacokinetics and biotransformation of 1,4-dihydropyridine calcium antagonists.Progress in Drug Metabolism, G. G. Gibson. Taylor & Francis, London 1990Vol. 12
  • Scherling D., Karl W., Ahr G., Ahr H. J., Wehinger E. Pharmacokinetics of nisoldipine III. Biotransformation of nitrendipine in rat, dog, monkey and man. Arzneimittel-Forschung 1988; 38: 1105–1110
  • Scherling D., Karl W., Ahr H. J., Kern A., Siefert H.-M. Biotransformation of nitrendipine in rat, dog and mouse. Arzneimittel-Forschung 1991; 41: 1009–1021
  • Takayama F., Iwasawa Y., Saito K., Shiratori K., Ohtawa M. Metabolism of a new dihydropyridine calcium antagonist in rats and dogs. Xenobiotica 1989; 19: 1407–1420
  • Taylor T., Taylor I. W., Chasseaud L. F., Bonn R. Pharmacokinetics and metabolism of organic nitrate vasodilatorsProgress in Drug Metabolism, J. W. Bridges, L. F. Chasseaud, G. G. Gibson. Taylor & Francis, London 1987Vol. 10
  • Terashita S., Tokuma Y., Fujiwara T., Shiokawa Y., Okumura K., Noguchi H. Metabolism of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. Xenobiotica 1987; 14: 1415–1425
  • Tsuchida K., Muramatsu M., Kaneko K., Yamazaki R., Yamada T., Ogawa N., Aihara H. CD-349. Cardiovascular Drug Reviews 1990; 8: 45–55
  • Tsuchida K., Yamazaki R., Kaneko K., Aihara H. Effects of the new calcium antagonist 2-nitratopropyl-3-nitratopropyl-2, 6-dimethyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-3, 5-di-carboxylate on cerebral circulation in dogs. Arzneimittel-Forschung 1987; 37: 1239–1243
  • Weidolf L., Borg K. O., Hoffmann K.-J. Urinary metabolites of felodipine, a new vasodilator drug, in man, dog, rat and mouse. Xenobiotica 1984; 14: 657–666
  • Weidolf L., Hoffmann K.-J. Physico-chemical properties of urinary metabolites of felodipine, a new vasodilator drug. Acta Pharmaceutica Suecica 1984; 21: 331–344

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.